EtoricoxibThird Party Manufacturing in India

Etoricoxib works by selectively inhibiting the cyclooxygenase-2 (COX-2) enzyme, which is responsible for the production of prostaglandins from arachidonic acid at sites of inflammation. Unlike traditional non-selective NSAIDs that also block COX-1, etoricoxib's specificity for COX-2 allows it to reduce pain and inflammation while having a reduced effect on COX-1-mediated gastrointestinal protection. This selectivity is the key pharmacological advantage of etoricoxib, resulting in effective analgesia and anti-inflammatory activity with a lower incidence of gastrointestinal ulcers and bleeding compared to conventional NSAIDs. As a sulfone-containing diarylpyridine compound, etoricoxib demonstrates high oral bioavailability and a long elimination half-life of approximately 22 hours, which supports convenient once-daily dosing. The drug is extensively metabolized in the liver, primarily via the CYP3A4 isoenzyme, and its metabolites are excreted mainly through urine and feces. Etoricoxib is approved in over 60 countries worldwide for the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, chronic low back pain, acute gouty arthritis, and dental pain.

Therapeutic Uses

Etoricoxib is prescribed for the treatment of:

• Osteoarthritis: Provides symptomatic relief from joint pain, stiffness, and inflammation at a recommended dose of 30-60 mg once daily.
• Rheumatoid Arthritis: Reduces inflammatory symptoms, swelling, and pain associated with rheumatoid arthritis.
• Ankylosing Spondylitis: Manages inflammatory back pain and spinal stiffness characteristic of this condition.
• Acute Gouty Arthritis: Delivers rapid relief from acute gout attacks at a dose of 120 mg once daily for short-term use.
• Chronic Low Back Pain: Offers effective pain management for persistent musculoskeletal back pain.
• Dental Pain: Provides short-term relief of moderate pain following dental surgery at 90 mg once daily.
• Primary Dysmenorrhoea: Relieves menstrual pain at 120 mg once daily for short-term use.

Why Manufacturers Choose Etoricoxib

Etoricoxib represents one of the most commercially successful COX-2 selective NSAIDs in the global pharmaceutical market. Its availability in multiple strengths (30mg, 60mg, 90mg, 120mg tablets and 1% topical gel) creates diverse product line opportunities for manufacturers. The molecule is particularly attractive for contract manufacturing in India due to its established regulatory acceptance across major markets, high prescription volumes in both domestic and export channels, and the availability of cost-effective API sources. Indian manufacturers can leverage the growing preference for COX-2 selective agents among physicians who prioritize gastrointestinal safety in chronic pain management. The molecule's strong brand recognition through innovator products like Arcoxia provides a solid market foundation for generic and PCD franchise versions.

This makes Etoricoxib one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.